Inhibition of mitochondrial sodium/calcium exchanger, NCLX, as a therapeutic strategy to reduce myocardial ischemia-reperfusion injury during myocardial infarction
VHIR is seeking an outstanding and highly motivated postdoctoral researcher to apply for a Marie Sklodowska-Curie Postdoctoral Fellowship in the field of mitochondrial biology, cardiovascular pathophysiology and translational cardio protection.
Marie Skłodowska-Curie Actions – Postdoctoral Fellowships (MSCA-PF)
The Marie Skłodowska-Curie Postdoctoral Fellowships (MSCA-PF) are part of the Horizon Europe programme and support postdoctoral researchers in developing an original research and innovation project through international mobility.
The programme aims to strengthen researchers’ careers through excellent science, international collaboration and interdisciplinary experience, while fostering integration in both academic and non-academic environments. The MSCA-PF call is highly competitive and represents an excellent opportunity to attract international talent and support researchers in consolidating their scientific careers through an ambitious mobility-based fellowship.
The 2026 call closes on 09/09/2026 (17:00 Brussels time). For candidates applying to a European Postdoctoral Fellowship, the fellowship duration is from 12 to 24 months
Full eligibility details: MSCA Postdoctoral Fellowships 2026
Background
Myocardial ischemia-reperfusion (IR) injury remains a major challenge in cardiovascular medicine. While rapid reperfusion improves survival after myocardial infarction, it paradoxically triggers additional myocardial damage, promoting infarct expansion and heart failure. Mitochondria play a central role via disruptions in energetics, calcium handling, and excessive reactive oxygen species (ROS) production. Recent studies identify the mitochondrial sodium/calcium exchanger NCLX (SLC8B1) as a key regulator of mitochondrial ROS signalling, linking sodium influx to electron transport chain dysfunction during hypoxia/reoxygenation. Notably, NCLX inhibition reduces ROS and tissue damage in cerebral ischemia models, suggesting a novel role for mitochondrial sodium in ischemic injury, still unexplored in the heart. Our preliminary data show that NCLX inhibition significantly reduces infarct size in cardiac IR models. This project combines cutting-edge mitochondrial biology with translational cardiovascular research to uncover how NCLX controls ROS production, mitochondrial function, and cardiomyocyte survival using advanced in vitro, ex vivo, in vivo, and human models. These findings may redefine reperfusion injury mechanisms and open new therapeutic strategies for ischemic heart disease.
Objective
The goal of this project is to determine whether the mitochondrial sodium/calcium exchanger NCLX is a key regulator of reactive oxygen species (ROS) production and myocardial injury during ischemia-reperfusion (IR), and to assess the therapeutic potential of its inhibition in acute myocardial infarction. The project will examine how NCLX controls mitochondrial sodium and calcium balance, respiratory chain function, and ROS generation during ischemia and reperfusion, as well as the molecular mechanisms linking NCLX activity to mitochondrial dysfunction and cardiomyocyte death. In parallel, the cardioprotective efficacy of novel NCLX inhibitors will be tested in isolated hearts, and in vivo rodent and pig models. By integrating mechanistic and translational approaches, this work aims to establish mitochondrial Na+/Ca2+ exchange as a novel therapeutic target in ischemic heart disease.
Our Group
The research group focuses on the molecular and translational mechanisms underlying cardiovascular disease, with particular expertise in myocardial ischemia-reperfusion injury, heart failure, adverse ventricular remodelling and cardiac arrhythmias. Its main research lines include the study of mitochondrial and cellular mechanisms of ischemia-reperfusion injury, heart failure progression, inflammatory signalling, cardiovascular aging and metabolic stress, as well as the impact of environmental factors such as air pollution on cardiac function. The group integrates mechanistic research in mitochondrial biology, redox signalling, calcium handling and inflammation with translational approaches using cellular systems, isolated organs, rodent and porcine models, and human cardiac samples.
Conduct high‑quality research aligned with project and lab objectives, including rigorous data collection, analysis, and literature review.
Collaborate with senior researchers in designing experiments, developing research protocols, and contributing to publications, reports, and grant proposals.
Present research findings within the team and at scientific conferences or seminars.
Provide guidance to junior researchers or graduate students and supervise Bachelor’s and Master’s students when applicable.
Engage in continuous professional development and work with the technology transfer office to identify potential inventions and understand IP processes.
Applicants must hold a PhD degree or have successfully defended their thesis before the call deadline (09/09/2026)
Applicants must comply with the mobility rule, meaning they must not have resided or carried out their main activity (work/studies) in the host country for more than 12 months during the 36 months prior to the call deadline.
Good publication track record, and written and oral communication skills in English.
Prior postdoctoral experience in cardiovascular research or metabolism. Official accreditation for work with laboratory animals.
Applicants must have a maximum of 8 years of postdoctoral research experience by the call deadline. This means candidates are generally eligible if they obtained their PhD on or after 10/09/2018 (possible extensions may apply, e.g. parental leave or long-term illness).
Solid background in cardiovascular physiology, cell biology or related fields.
Previous hand-on research experience in molecular and cellular biology techniques, including Western blotting, RT-qPCR, immunofluorescence and biochemical assays.
Knowledge of mitochondrial physiology and live-cell imaging techniques.
Basic skills in statistical analysis and scientific programming/data analysis.
Deadline to apply: 31-07-2026
VHIR embraces Equality and Diversity. As reflected in our values we work toward ensuring inclusion and equal opportunity in recruitment, hiring, training, and management for all staff within the organisation, regardless of gender, civil status, family status, sexual orientation, gender identity and expression, religion, age, functional diversity or ethnicity.
Information on Personal Data Protection:
Data Controller: Fundació Hospital Universitari Vall d’Hebron Institut de Recerca -VHIR-. Purpose: Personnel selection. Legal Basis: Your consent. Data retention period: One year. If you are selected, as long as the employment relationship is in force and legal responsibilities may arise. Data sharing: Does not occur, except for communications necessary to fulfill the purpose and those required by law to public and private bodies. Rights: You can access, rectify, delete, object to, and limit the processing of data, as well as request data portability where applicable, by contacting lopd@vhir.org DPO: dpd@ticsalutsocial.cat More information can be found here
Data Protection Authority: APDCAT
We are a public sector institution that promotes and develops the biomedical research, innovation and teaching at Vall d'Hebron University Hospital, the hospital of Barcelona and the largest of Catalan Institute of Health (ICS). The members of our Board of Trustees are the Catalan Ministry of Health, the Catalan Ministry of Economy and Knowledge (we are a CERCA center), Vall d'Hebron University Hospital, Bank of blood and tissues, the Autonomous University of Barcelona (UAB), of which we are an accredited research institute, and the Vall d'Hebron Institute of Oncology (VHIO), which together with VHIR is part of Accredited Institute of Campus Vall d’Hebron Institute by the Institute of Health Carlos III (ISCIII).
Since its creation in 1994, VHIR works to find solutions to the health problems of society, and contribute to spread them around the world. In more than 20 years we have achieved leadership in biomedical research at hospitals in our country, and we want to be recognised in 2020 as an excellent and competitive European Institute leader in clinical and traslational research linked to a university hospital.
In our institute are working more than 1,300 people, of which over 1,200 doing research and others, around 100, help to do it or transfer it to the society once made, whether in the form of projects, technology transfer and innovation, communication or fundraising, among others.
The best of our institution and its research staff is doing research to solve people’s health problems. Our task is not only basic or translational, we are leaders in clinical research. We have the beds of the hospital separated in less than 50 meters of laboratories and our patients will benefit from our research. In this we believe, and our efforts are focused on it. This is understood by industry leaders who are committed to our hospital, making it a world reference for its first clinical trials.
